Research by the Pere Virgili Health Research Institute (IISPV) and the Rovira i Virgili University (URV) have culminated in the formation of RetinaReadRisk, a cutting-edge spin-off poised to transform the early detection and treatment of diabetic retinopathy. This common eye condition afflicts individuals with type 2 diabetes, affecting approximately 25% of Spain’s population.

RetinaReadRisk pioneers the integration of artificial intelligence (AI) into healthcare, offering software and a mobile system designed to detect and manage diabetic retinopathy in its nascent stages. At the heart of this innovation are two groundbreaking software solutions: Mira and Retiprogram.

Mira utilizes Deep Learning technology to automatically analyze fundus images of the patient’s eye, accurately identifying the presence and severity of diabetic retinopathy. Meanwhile, Retiprogram assesses an individual’s risk of developing diabetic retinopathy based on clinical and personal data, determining optimal follow-up intervals.

The significance of RetinaReadRisk extends beyond technological innovation. By streamlining the diagnostic process and enabling remote screening, the spin-off aims to enhance access to care, particularly in underserved areas.

Article written by Cristina Aluja



Institut d’investigació sanitaria Pere Virgili